Kupando Secures Additional €10 Million in Series A Financing to Advance Novel Immuno-Oncology and Infectious Diseases Programs by Bettina Hanika | Mar 18, 2026 | Press Releases
Kupando Appoints Biotech Industry Veteran Jörn Aldag as Chair to Accelerate Development of TLR 4/7 Agonist Platform by Bettina Hanika | Feb 3, 2026 | Press Releases
Kupando raises €13 million in Series A funding round by Bettina Hanika | Sep 26, 2022 | Press Releases
